$PGNX Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in PROGENICS PHARMACEUTICALS INC.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in PROGENICS PHARMACEUTICALS INC. Get notifications about new insider transactions in PROGENICS PHARMACEUTICALS INC for free.
Page: < prev 1 ... 2 3 4 5 6 7 8 9 ... 13 next >
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Oct 05 2009 | PGNX | PROGENICS PHARMACE ... | MCKINNEY ROBERT A | Chief Financial Off ... | Buy | M | 4.26 | 2,666 | 11,354 | 38,377 | 35.7 K to 38.4 K (+7.47 %) |
| Oct 05 2009 | PGNX | PROGENICS PHARMACE ... | ISRAEL ROBERT J | Sr. VP, Medical Aff ... | Option Exercise | A | 5.24 | 3,042 | 15,940 | 3,042 | |
| Oct 05 2009 | PGNX | PROGENICS PHARMACE ... | ISRAEL ROBERT J | Sr. VP, Medical Aff ... | Option Exercise | M | 4.26 | 3,578 | 15,239 | 0 | |
| Oct 05 2009 | PGNX | PROGENICS PHARMACE ... | ISRAEL ROBERT J | Sr. VP, Medical Aff ... | Payment of Exercise | F | 5.01 | 3,256 | 16,313 | 43,270 | 46.5 K to 43.3 K (-7.00 %) |
| Oct 05 2009 | PGNX | PROGENICS PHARMACE ... | ISRAEL ROBERT J | Sr. VP, Medical Aff ... | Buy | M | 4.26 | 3,578 | 15,239 | 46,526 | 42.9 K to 46.5 K (+8.33 %) |
| Oct 05 2009 | PGNX | PROGENICS PHARMACE ... | Baker Mark Robert | General Counsel | Option Exercise | A | 5.24 | 3,399 | 17,811 | 3,399 | |
| Oct 05 2009 | PGNX | PROGENICS PHARMACE ... | Baker Mark Robert | General Counsel | Option Exercise | M | 4.26 | 3,999 | 17,032 | 0 | |
| Oct 05 2009 | PGNX | PROGENICS PHARMACE ... | Baker Mark Robert | General Counsel | Payment of Exercise | F | 5.01 | 3,639 | 18,231 | 29,915 | 33.6 K to 29.9 K (-10.85 %) |
| Oct 05 2009 | PGNX | PROGENICS PHARMACE ... | Baker Mark Robert | General Counsel | Buy | M | 4.26 | 3,999 | 17,032 | 33,554 | 29.6 K to 33.6 K (+13.53 %) |
| Oct 05 2009 | PGNX | PROGENICS PHARMACE ... | Boyd Thomas A | Sr. VP, Product Dev ... | Option Exercise | A | 5.24 | 2,266 | 11,874 | 2,266 | |
| Oct 05 2009 | PGNX | PROGENICS PHARMACE ... | Boyd Thomas A | Sr. VP, Product Dev ... | Option Exercise | M | 4.26 | 2,666 | 11,354 | 0 | |
| Oct 05 2009 | PGNX | PROGENICS PHARMACE ... | Boyd Thomas A | Sr. VP, Product Dev ... | Payment of Exercise | F | 5.01 | 2,426 | 12,154 | 38,060 | 40.5 K to 38.1 K (-5.99 %) |
| Oct 05 2009 | PGNX | PROGENICS PHARMACE ... | Boyd Thomas A | Sr. VP, Product Dev ... | Buy | M | 4.26 | 2,666 | 11,354 | 40,486 | 37.8 K to 40.5 K (+7.05 %) |
| Jul 06 2009 | PGNX | PROGENICS PHARMACE ... | SCHEINBERG DAVID A | Director | Option Exercise | A | 5.33 | 10,000 | 53,300 | 10,000 | |
| Jul 06 2009 | PGNX | PROGENICS PHARMACE ... | WILLIAMS NICOLE | Director | Option Exercise | A | 5.33 | 10,000 | 53,300 | 10,000 | |
| Jul 06 2009 | PGNX | PROGENICS PHARMACE ... | GOFF STEPHEN P | Director | Option Exercise | A | 5.33 | 10,000 | 53,300 | 10,000 | |
| Jul 06 2009 | PGNX | PROGENICS PHARMACE ... | DALTON MARK F | Director | Option Exercise | A | 5.33 | 10,000 | 53,300 | 10,000 | |
| Jul 06 2009 | PGNX | PROGENICS PHARMACE ... | BRINER KURT W | Director | Option Exercise | A | 5.33 | 25,000 | 133,250 | 25,000 | |
| Jul 06 2009 | PGNX | PROGENICS PHARMACE ... | Crowley Peter J | Director | Option Exercise | A | 5.33 | 10,000 | 53,300 | 10,000 | |
| Jul 06 2009 | PGNX | PROGENICS PHARMACE ... | BAKER CHARLES A | Director | Option Exercise | A | 5.33 | 10,000 | 53,300 | 10,000 | |
| Jul 06 2009 | PGNX | PROGENICS PHARMACE ... | Olson William C | VP, Research & Deve ... | Option Exercise | A | 5.33 | 50,000 | 266,500 | 50,000 | |
| Jul 06 2009 | PGNX | PROGENICS PHARMACE ... | Olson William C | VP, Research & Deve ... | Option Exercise | M | 5.33 | 6,461 | 34,437 | 0 | |
| Jul 06 2009 | PGNX | PROGENICS PHARMACE ... | Olson William C | VP, Research & Deve ... | Option Exercise | A | 5.15 | 2,191 | 11,284 | 2,191 | |
| Jul 06 2009 | PGNX | PROGENICS PHARMACE ... | Olson William C | VP, Research & Deve ... | Payment of Exercise | F | 5.33 | 5,880 | 31,340 | 36,472 | 42.4 K to 36.5 K (-13.88 %) |
| Jul 06 2009 | PGNX | PROGENICS PHARMACE ... | Olson William C | VP, Research & Deve ... | Buy | M | 5.33 | 6,461 | 34,437 | 42,352 | 35.9 K to 42.4 K (+18.00 %) |
| Jul 06 2009 | PGNX | PROGENICS PHARMACE ... | MCKINNEY ROBERT A | Chief Financial Off ... | Option Exercise | A | 5.33 | 50,000 | 266,500 | 50,000 | |
| Jul 06 2009 | PGNX | PROGENICS PHARMACE ... | MCKINNEY ROBERT A | Chief Financial Off ... | Option Exercise | M | 5.33 | 7,738 | 41,244 | 0 | |
| Jul 06 2009 | PGNX | PROGENICS PHARMACE ... | MCKINNEY ROBERT A | Chief Financial Off ... | Option Exercise | A | 5.15 | 2,306 | 11,876 | 2,306 | |
| Jul 06 2009 | PGNX | PROGENICS PHARMACE ... | MCKINNEY ROBERT A | Chief Financial Off ... | Payment of Exercise | F | 5.33 | 7,041 | 37,529 | 35,501 | 42.5 K to 35.5 K (-16.55 %) |
| Jul 06 2009 | PGNX | PROGENICS PHARMACE ... | MCKINNEY ROBERT A | Chief Financial Off ... | Buy | M | 5.33 | 7,738 | 41,244 | 42,542 | 34.8 K to 42.5 K (+22.23 %) |
| Jul 06 2009 | PGNX | PROGENICS PHARMACE ... | ISRAEL ROBERT J | Sr. VP, Medical Aff ... | Option Exercise | A | 5.33 | 50,000 | 266,500 | 50,000 | |
| Jul 06 2009 | PGNX | PROGENICS PHARMACE ... | ISRAEL ROBERT J | Sr. VP, Medical Aff ... | Option Exercise | M | 5.33 | 8,210 | 43,759 | 0 | |
| Jul 06 2009 | PGNX | PROGENICS PHARMACE ... | ISRAEL ROBERT J | Sr. VP, Medical Aff ... | Option Exercise | A | 5.15 | 3,095 | 15,939 | 3,095 | |
| Jul 06 2009 | PGNX | PROGENICS PHARMACE ... | ISRAEL ROBERT J | Sr. VP, Medical Aff ... | Payment of Exercise | F | 5.33 | 7,471 | 39,820 | 42,738 | 50.2 K to 42.7 K (-14.88 %) |
| Jul 06 2009 | PGNX | PROGENICS PHARMACE ... | ISRAEL ROBERT J | Sr. VP, Medical Aff ... | Buy | M | 5.33 | 8,210 | 43,759 | 50,209 | 42 K to 50.2 K (+19.55 %) |
| Jul 06 2009 | PGNX | PROGENICS PHARMACE ... | Boyd Thomas A | Sr. VP, Product Dev ... | Option Exercise | A | 5.33 | 50,000 | 266,500 | 50,000 | |
| Jul 06 2009 | PGNX | PROGENICS PHARMACE ... | Boyd Thomas A | Sr. VP, Product Dev ... | Option Exercise | M | 5.33 | 7,738 | 41,244 | 0 | |
| Jul 06 2009 | PGNX | PROGENICS PHARMACE ... | Boyd Thomas A | Sr. VP, Product Dev ... | Option Exercise | A | 5.15 | 2,306 | 11,876 | 2,306 | |
| Jul 06 2009 | PGNX | PROGENICS PHARMACE ... | Boyd Thomas A | Sr. VP, Product Dev ... | Payment of Exercise | F | 5.33 | 7,041 | 37,529 | 37,610 | 44.7 K to 37.6 K (-15.77 %) |
| Jul 06 2009 | PGNX | PROGENICS PHARMACE ... | Boyd Thomas A | Sr. VP, Product Dev ... | Buy | M | 5.33 | 7,738 | 41,244 | 44,651 | 36.9 K to 44.7 K (+20.96 %) |
| Jul 06 2009 | PGNX | PROGENICS PHARMACE ... | Baker Mark Robert | General Counsel | Option Exercise | A | 5.33 | 100,000 | 533,000 | 100,000 | |
| Jul 06 2009 | PGNX | PROGENICS PHARMACE ... | Baker Mark Robert | General Counsel | Option Exercise | M | 5.33 | 13,207 | 70,393 | 0 | |
| Jul 06 2009 | PGNX | PROGENICS PHARMACE ... | Baker Mark Robert | General Counsel | Option Exercise | A | 5.15 | 3,459 | 17,814 | 3,459 | |
| Jul 06 2009 | PGNX | PROGENICS PHARMACE ... | Baker Mark Robert | General Counsel | Payment of Exercise | F | 5.33 | 12,018 | 64,056 | 29,345 | 41.4 K to 29.3 K (-29.05 %) |
| Jul 06 2009 | PGNX | PROGENICS PHARMACE ... | Baker Mark Robert | General Counsel | Buy | M | 5.33 | 13,207 | 70,393 | 41,363 | 28.2 K to 41.4 K (+46.91 %) |
| Jul 06 2009 | PGNX | PROGENICS PHARMACE ... | MADDON PAUL J | Chief Executive Off ... | Option Exercise | A | 5.33 | 175,000 | 932,750 | 175,000 | |
| Jun 24 2009 | PGNX | PROGENICS PHARMACE ... | Olson William C | VP, Research & Deve ... | Sell | S | 4.73 | 2,500 | 11,815 | 35,677 | 38.2 K to 35.7 K (-6.55 %) |
| Jun 22 2009 | PGNX | PROGENICS PHARMACE ... | MCKINNEY ROBERT A | Chief Financial Off ... | Sell | S | 5.25 | 5,000 | 26,265 | 34,590 | 39.6 K to 34.6 K (-12.63 %) |
| Jun 24 2009 | PGNX | PROGENICS PHARMACE ... | Boyd Thomas A | Sr. VP, Product Dev ... | Sell | S | 4.73 | 2,000 | 9,468 | 36,699 | 38.7 K to 36.7 K (-5.17 %) |
| Apr 22 2009 | PGNX | PROGENICS PHARMACE ... | WILLIAMS NICOLE | Director | Grant | A | 5.45 | 1,000 | 5,448 | 5,000 | 4 K to 5 K (+25.00 %) |
| Apr 22 2009 | PGNX | PROGENICS PHARMACE ... | WILLIAMS NICOLE | Director | Grant | A | 5.39 | 1,000 | 5,385 | 4,000 | 3 K to 4 K (+33.33 %) |
| Apr 22 2009 | PGNX | PROGENICS PHARMACE ... | WILLIAMS NICOLE | Director | Grant | A | 5.38 | 1,000 | 5,383 | 3,000 | 2 K to 3 K (+50.00 %) |
| Apr 22 2009 | PGNX | PROGENICS PHARMACE ... | WILLIAMS NICOLE | Director | Grant | A | 5.29 | 1,000 | 5,286 | 2,000 | 1,000 to 2 K (+100.00 %) |
| Apr 22 2009 | PGNX | PROGENICS PHARMACE ... | WILLIAMS NICOLE | Director | Grant | A | 5.48 | 1,000 | 5,482 | 1,000 | 0 to 1,000 |
| Apr 03 2009 | PGNX | PROGENICS PHARMACE ... | Olson William C | VP, Research & Deve ... | Option Exercise | A | 6.59 | 1,712 | 11,282 | 1,712 | |
| Apr 03 2009 | PGNX | PROGENICS PHARMACE ... | Olson William C | VP, Research & Deve ... | Option Exercise | M | 5.65 | 2,014 | 11,379 | 0 | |
| Apr 03 2009 | PGNX | PROGENICS PHARMACE ... | Olson William C | VP, Research & Deve ... | Buy | M | 5.65 | 2,014 | 11,379 | 38,177 | 36.2 K to 38.2 K (+5.57 %) |
| Apr 03 2009 | PGNX | PROGENICS PHARMACE ... | Olson William C | VP, Research & Deve ... | Payment of Exercise | F | 6.65 | 1,832 | 12,183 | 36,163 | 38 K to 36.2 K (-4.82 %) |
| Apr 03 2009 | PGNX | PROGENICS PHARMACE ... | MCKINNEY ROBERT A | Chief Financial Off ... | Option Exercise | A | 6.59 | 1,802 | 11,875 | 1,802 | |
| Apr 03 2009 | PGNX | PROGENICS PHARMACE ... | MCKINNEY ROBERT A | Chief Financial Off ... | Option Exercise | M | 5.65 | 2,120 | 11,978 | 0 | |
| Apr 03 2009 | PGNX | PROGENICS PHARMACE ... | MCKINNEY ROBERT A | Chief Financial Off ... | Buy | M | 5.65 | 2,120 | 11,978 | 39,590 | 37.5 K to 39.6 K (+5.66 %) |
| Apr 03 2009 | PGNX | PROGENICS PHARMACE ... | MCKINNEY ROBERT A | Chief Financial Off ... | Payment of Exercise | F | 6.65 | 1,929 | 12,828 | 37,470 | 39.4 K to 37.5 K (-4.90 %) |
| Apr 03 2009 | PGNX | PROGENICS PHARMACE ... | ISRAEL ROBERT J | Sr. VP, Medical Aff ... | Option Exercise | A | 6.59 | 2,418 | 15,935 | 2,418 | |
| Apr 03 2009 | PGNX | PROGENICS PHARMACE ... | ISRAEL ROBERT J | Sr. VP, Medical Aff ... | Option Exercise | M | 5.65 | 2,845 | 16,074 | 0 | |
| Apr 03 2009 | PGNX | PROGENICS PHARMACE ... | ISRAEL ROBERT J | Sr. VP, Medical Aff ... | Buy | M | 5.65 | 2,845 | 16,074 | 41,785 | 38.9 K to 41.8 K (+7.31 %) |
| Apr 03 2009 | PGNX | PROGENICS PHARMACE ... | ISRAEL ROBERT J | Sr. VP, Medical Aff ... | Payment of Exercise | F | 6.65 | 2,588 | 17,210 | 38,940 | 41.5 K to 38.9 K (-6.23 %) |
| Apr 03 2009 | PGNX | PROGENICS PHARMACE ... | Boyd Thomas A | Sr. VP, Product Dev ... | Option Exercise | A | 6.59 | 1,802 | 11,875 | 1,802 | |
| Apr 03 2009 | PGNX | PROGENICS PHARMACE ... | Boyd Thomas A | Sr. VP, Product Dev ... | Option Exercise | M | 5.65 | 2,120 | 11,978 | 0 | |
| Apr 03 2009 | PGNX | PROGENICS PHARMACE ... | Boyd Thomas A | Sr. VP, Product Dev ... | Buy | M | 5.65 | 2,120 | 11,978 | 38,699 | 36.6 K to 38.7 K (+5.80 %) |
| Apr 03 2009 | PGNX | PROGENICS PHARMACE ... | Boyd Thomas A | Sr. VP, Product Dev ... | Payment of Exercise | F | 6.65 | 1,929 | 12,828 | 36,579 | 38.5 K to 36.6 K (-5.01 %) |
| Apr 03 2009 | PGNX | PROGENICS PHARMACE ... | Baker Mark Robert | General Counsel | Option Exercise | A | 6.59 | 2,703 | 17,813 | 2,703 | |
| Apr 03 2009 | PGNX | PROGENICS PHARMACE ... | Baker Mark Robert | General Counsel | Option Exercise | M | 5.65 | 3,180 | 17,967 | 0 | |
| Apr 03 2009 | PGNX | PROGENICS PHARMACE ... | Baker Mark Robert | General Counsel | Buy | M | 5.65 | 3,180 | 17,967 | 27,942 | 24.8 K to 27.9 K (+12.84 %) |
| Apr 03 2009 | PGNX | PROGENICS PHARMACE ... | Baker Mark Robert | General Counsel | Payment of Exercise | F | 6.65 | 2,893 | 19,238 | 24,762 | 27.7 K to 24.8 K (-10.46 %) |
| Mar 23 2009 | PGNX | PROGENICS PHARMACE ... | MADDON PAUL J | Chief Executive Off ... | Grant | A | 0.00 | 66,294 | 0 | 786,442 | 720.1 K to 786.4 K (+9.21 %) |
| Feb 03 2009 | PGNX | PROGENICS PHARMACE ... | Crowley Peter J | Director | Option Exercise | A | 7.45 | 25,000 | 186,250 | 25,000 | |
| Jan 06 2009 | PGNX | PROGENICS PHARMACE ... | Olson William C | VP, Research & Deve ... | Option Exercise | A | 10.31 | 2,307 | 23,785 | 2,307 | |
| Jan 06 2009 | PGNX | PROGENICS PHARMACE ... | Olson William C | VP, Research & Deve ... | Option Exercise | M | 9.13 | 1,287 | 11,750 | 0 | |
| Jan 06 2009 | PGNX | PROGENICS PHARMACE ... | Olson William C | VP, Research & Deve ... | Payment of Exercise | F | 10.74 | 1,171 | 12,577 | 37,827 | 39 K to 37.8 K (-3.00 %) |
| Jan 06 2009 | PGNX | PROGENICS PHARMACE ... | Olson William C | VP, Research & Deve ... | Buy | M | 9.13 | 1,287 | 11,750 | 38,998 | 37.7 K to 39 K (+3.41 %) |
| Jan 06 2009 | PGNX | PROGENICS PHARMACE ... | MCKINNEY ROBERT A | Chief Financial Off ... | Option Exercise | A | 10.31 | 2,364 | 24,373 | 2,364 | |
| Jan 06 2009 | PGNX | PROGENICS PHARMACE ... | MCKINNEY ROBERT A | Chief Financial Off ... | Option Exercise | M | 9.13 | 1,355 | 12,371 | 0 | |
| Jan 06 2009 | PGNX | PROGENICS PHARMACE ... | MCKINNEY ROBERT A | Chief Financial Off ... | Payment of Exercise | F | 10.74 | 1,233 | 13,242 | 39,231 | 40.5 K to 39.2 K (-3.05 %) |
| Jan 06 2009 | PGNX | PROGENICS PHARMACE ... | MCKINNEY ROBERT A | Chief Financial Off ... | Buy | M | 9.13 | 1,355 | 12,371 | 40,464 | 39.1 K to 40.5 K (+3.46 %) |
| Jan 06 2009 | PGNX | PROGENICS PHARMACE ... | ISRAEL ROBERT J | Sr. VP, Medical Aff ... | Option Exercise | A | 10.31 | 2,758 | 28,435 | 2,758 | |
| Jan 06 2009 | PGNX | PROGENICS PHARMACE ... | ISRAEL ROBERT J | Sr. VP, Medical Aff ... | Option Exercise | M | 9.13 | 1,819 | 16,607 | 0 | |
| Jan 06 2009 | PGNX | PROGENICS PHARMACE ... | ISRAEL ROBERT J | Sr. VP, Medical Aff ... | Payment of Exercise | F | 10.74 | 1,654 | 17,764 | 41,360 | 43 K to 41.4 K (-3.85 %) |
| Jan 06 2009 | PGNX | PROGENICS PHARMACE ... | ISRAEL ROBERT J | Sr. VP, Medical Aff ... | Buy | M | 9.13 | 1,819 | 16,607 | 43,014 | 41.2 K to 43 K (+4.42 %) |
| Jan 06 2009 | PGNX | PROGENICS PHARMACE ... | Boyd Thomas A | Sr. VP, Product Dev ... | Option Exercise | A | 10.31 | 2,364 | 24,373 | 2,364 | |
| Jan 06 2009 | PGNX | PROGENICS PHARMACE ... | Boyd Thomas A | Sr. VP, Product Dev ... | Option Exercise | M | 9.13 | 1,355 | 12,371 | 0 | |
| Jan 06 2009 | PGNX | PROGENICS PHARMACE ... | Boyd Thomas A | Sr. VP, Product Dev ... | Payment of Exercise | F | 10.74 | 1,233 | 13,242 | 38,340 | 39.6 K to 38.3 K (-3.12 %) |
| Jan 06 2009 | PGNX | PROGENICS PHARMACE ... | Boyd Thomas A | Sr. VP, Product Dev ... | Buy | M | 9.13 | 1,355 | 12,371 | 39,573 | 38.2 K to 39.6 K (+3.55 %) |
| Jan 06 2009 | PGNX | PROGENICS PHARMACE ... | Baker Mark Robert | General Counsel | Option Exercise | A | 10.31 | 4,153 | 42,817 | 4,153 | |
| Jan 06 2009 | PGNX | PROGENICS PHARMACE ... | Baker Mark Robert | General Counsel | Option Exercise | M | 9.13 | 2,033 | 18,561 | 0 | |
| Jan 06 2009 | PGNX | PROGENICS PHARMACE ... | Baker Mark Robert | General Counsel | Payment of Exercise | F | 10.74 | 1,849 | 19,858 | 27,487 | 29.3 K to 27.5 K (-6.30 %) |
| Jan 06 2009 | PGNX | PROGENICS PHARMACE ... | Baker Mark Robert | General Counsel | Buy | M | 9.13 | 2,033 | 18,561 | 29,336 | 27.3 K to 29.3 K (+7.45 %) |
| Oct 24 2008 | PGNX | PROGENICS PHARMACE ... | JACOBSON PAUL F | Director | Sell | S | 9.05 | 27,000 | 244,458 | 125,600 | 152.6 K to 125.6 K (-17.69 %) |
| Oct 24 2008 | PGNX | PROGENICS PHARMACE ... | JACOBSON PAUL F | Director | Sell | S | 9.39 | 35,500 | 333,168 | 152,600 | 188.1 K to 152.6 K (-18.87 %) |
| Oct 03 2008 | PGNX | PROGENICS PHARMACE ... | Olson William C | VP, Research & Deve ... | Option Exercise | A | 13.31 | 848 | 11,287 | 848 | |
| Oct 03 2008 | PGNX | PROGENICS PHARMACE ... | Olson William C | VP, Research & Deve ... | Option Exercise | M | 6.53 | 1,484 | 9,691 | 0 | |
| Oct 03 2008 | PGNX | PROGENICS PHARMACE ... | Olson William C | VP, Research & Deve ... | Payment of Exercise | F | 13.93 | 1,011 | 14,083 | 37,604 | 38.6 K to 37.6 K (-2.62 %) |
| Oct 03 2008 | PGNX | PROGENICS PHARMACE ... | Olson William C | VP, Research & Deve ... | Buy | M | 6.53 | 1,484 | 9,691 | 38,615 | 37.1 K to 38.6 K (+4.00 %) |
| Oct 03 2008 | PGNX | PROGENICS PHARMACE ... | MCKINNEY ROBERT A | Chief Financial Off ... | Option Exercise | A | 13.31 | 892 | 11,873 | 892 | |
| Oct 03 2008 | PGNX | PROGENICS PHARMACE ... | MCKINNEY ROBERT A | Chief Financial Off ... | Option Exercise | M | 6.53 | 1,819 | 11,878 | 0 | |
| Oct 03 2008 | PGNX | PROGENICS PHARMACE ... | MCKINNEY ROBERT A | Chief Financial Off ... | Payment of Exercise | F | 13.93 | 1,239 | 17,259 | 39,002 | 40.2 K to 39 K (-3.08 %) |
| Oct 03 2008 | PGNX | PROGENICS PHARMACE ... | MCKINNEY ROBERT A | Chief Financial Off ... | Buy | M | 6.53 | 1,819 | 11,878 | 40,241 | 38.4 K to 40.2 K (+4.73 %) |
| Oct 03 2008 | PGNX | PROGENICS PHARMACE ... | ISRAEL ROBERT J | Sr. VP, Medical Aff ... | Option Exercise | A | 13.31 | 1,197 | 15,932 | 1,197 | |
| Oct 03 2008 | PGNX | PROGENICS PHARMACE ... | ISRAEL ROBERT J | Sr. VP, Medical Aff ... | Option Exercise | M | 6.53 | 2,441 | 15,940 | 0 | |
| Oct 03 2008 | PGNX | PROGENICS PHARMACE ... | ISRAEL ROBERT J | Sr. VP, Medical Aff ... | Payment of Exercise | F | 13.93 | 1,663 | 23,166 | 41,088 | 42.8 K to 41.1 K (-3.89 %) |
| Oct 03 2008 | PGNX | PROGENICS PHARMACE ... | ISRAEL ROBERT J | Sr. VP, Medical Aff ... | Buy | M | 6.53 | 2,441 | 15,940 | 42,751 | 40.3 K to 42.8 K (+6.06 %) |
| Oct 03 2008 | PGNX | PROGENICS PHARMACE ... | Boyd Thomas A | Sr. VP, Product Dev ... | Option Exercise | A | 13.31 | 892 | 11,873 | 892 | |
| Oct 03 2008 | PGNX | PROGENICS PHARMACE ... | Boyd Thomas A | Sr. VP, Product Dev ... | Option Exercise | M | 6.53 | 4,384 | 28,628 | 0 | |
| Oct 03 2008 | PGNX | PROGENICS PHARMACE ... | Boyd Thomas A | Sr. VP, Product Dev ... | Payment of Exercise | F | 13.93 | 2,987 | 41,609 | 38,111 | 41.1 K to 38.1 K (-7.27 %) |
| Oct 03 2008 | PGNX | PROGENICS PHARMACE ... | Boyd Thomas A | Sr. VP, Product Dev ... | Buy | M | 6.53 | 4,384 | 28,628 | 41,098 | 36.7 K to 41.1 K (+11.94 %) |
| Oct 03 2008 | PGNX | PROGENICS PHARMACE ... | Baker Mark Robert | General Counsel | Option Exercise | A | 13.31 | 1,338 | 17,809 | 1,338 | |
| Oct 03 2008 | PGNX | PROGENICS PHARMACE ... | Baker Mark Robert | General Counsel | Option Exercise | M | 6.53 | 2,393 | 15,626 | 0 | |
| Oct 03 2008 | PGNX | PROGENICS PHARMACE ... | Baker Mark Robert | General Counsel | Payment of Exercise | F | 13.93 | 1,631 | 22,720 | 27,196 | 28.8 K to 27.2 K (-5.66 %) |
| Oct 03 2008 | PGNX | PROGENICS PHARMACE ... | Baker Mark Robert | General Counsel | Buy | M | 6.53 | 2,393 | 15,626 | 28,827 | 26.4 K to 28.8 K (+9.05 %) |
| Aug 29 2008 | PGNX | PROGENICS PHARMACE ... | BRINER KURT W | Director | Option Exercise | M | 9.63 | 50,000 | 481,250 | 0 | |
| Aug 29 2008 | PGNX | PROGENICS PHARMACE ... | BRINER KURT W | Director | Buy | M | 9.63 | 50,000 | 481,250 | 53,000 | 3 K to 53 K (+1,666.67 %) |
| Sep 04 2008 | PGNX | PROGENICS PHARMACE ... | ISRAEL ROBERT J | Sr. VP, Medical Aff ... | Option Exercise | M | 12.29 | 1,000 | 12,290 | 25,000 | |
| Sep 04 2008 | PGNX | PROGENICS PHARMACE ... | ISRAEL ROBERT J | Sr. VP, Medical Aff ... | Sell | S | 15.00 | 1,000 | 15,000 | 39,801 | 40.8 K to 39.8 K (-2.45 %) |
| Sep 04 2008 | PGNX | PROGENICS PHARMACE ... | ISRAEL ROBERT J | Sr. VP, Medical Aff ... | Buy | M | 12.29 | 1,000 | 12,290 | 40,801 | 39.8 K to 40.8 K (+2.51 %) |
| Aug 05 2008 | PGNX | PROGENICS PHARMACE ... | ISRAEL ROBERT J | Sr. VP, Medical Aff ... | Option Exercise | M | 12.29 | 1,000 | 12,290 | 26,000 | |
| Aug 05 2008 | PGNX | PROGENICS PHARMACE ... | ISRAEL ROBERT J | Sr. VP, Medical Aff ... | Sell | S | 16.47 | 1,000 | 16,465 | 39,801 | 40.8 K to 39.8 K (-2.45 %) |
| Aug 05 2008 | PGNX | PROGENICS PHARMACE ... | ISRAEL ROBERT J | Sr. VP, Medical Aff ... | Buy | M | 12.29 | 1,000 | 12,290 | 40,801 | 39.8 K to 40.8 K (+2.51 %) |
| Jul 17 2008 | PGNX | PROGENICS PHARMACE ... | JACOBSON PAUL F | Director | Option Exercise | M | 11.44 | 2,500 | 28,595 | 0 | |
| Jul 17 2008 | PGNX | PROGENICS PHARMACE ... | JACOBSON PAUL F | Director | Option Exercise | M | 6.66 | 2,500 | 16,650 | 0 | |
| Jul 17 2008 | PGNX | PROGENICS PHARMACE ... | JACOBSON PAUL F | Director | Option Exercise | M | 5.02 | 2,500 | 12,550 | 0 | |
| Jul 17 2008 | PGNX | PROGENICS PHARMACE ... | JACOBSON PAUL F | Director | Option Exercise | M | 4.41 | 2,500 | 11,025 | 0 | |
| Jul 17 2008 | PGNX | PROGENICS PHARMACE ... | JACOBSON PAUL F | Director | Sell | S | 16.04 | 2,500 | 40,088 | 188,000 | 190.5 K to 188 K (-1.31 %) |
| Jul 17 2008 | PGNX | PROGENICS PHARMACE ... | JACOBSON PAUL F | Director | Buy | M | 6.66 | 2,500 | 16,650 | 190,500 | 188 K to 190.5 K (+1.33 %) |
| Jul 17 2008 | PGNX | PROGENICS PHARMACE ... | JACOBSON PAUL F | Director | Sell | S | 16.04 | 2,500 | 40,088 | 188,000 | 190.5 K to 188 K (-1.31 %) |
| Jul 17 2008 | PGNX | PROGENICS PHARMACE ... | JACOBSON PAUL F | Director | Buy | M | 5.02 | 2,500 | 12,550 | 190,500 | 188 K to 190.5 K (+1.33 %) |
| Jul 17 2008 | PGNX | PROGENICS PHARMACE ... | JACOBSON PAUL F | Director | Sell | S | 16.04 | 2,500 | 40,088 | 188,000 | 190.5 K to 188 K (-1.31 %) |
| Jul 17 2008 | PGNX | PROGENICS PHARMACE ... | JACOBSON PAUL F | Director | Buy | M | 4.41 | 2,500 | 11,025 | 190,500 | 188 K to 190.5 K (+1.33 %) |
| Jul 17 2008 | PGNX | PROGENICS PHARMACE ... | JACOBSON PAUL F | Director | Sell | S | 16.04 | 2,500 | 40,088 | 188,000 | 190.5 K to 188 K (-1.31 %) |
| Jul 17 2008 | PGNX | PROGENICS PHARMACE ... | JACOBSON PAUL F | Director | Buy | M | 11.44 | 2,500 | 28,595 | 190,500 | 188 K to 190.5 K (+1.33 %) |
| Jul 07 2008 | PGNX | PROGENICS PHARMACE ... | WILLIAMS NICOLE | Director | Option Exercise | A | 16.05 | 10,000 | 160,500 | 10,000 | |
| Jul 07 2008 | PGNX | PROGENICS PHARMACE ... | JACOBSON PAUL F | Director | Option Exercise | A | 16.05 | 25,000 | 401,250 | 25,000 | |
| Jul 07 2008 | PGNX | PROGENICS PHARMACE ... | SCHEINBERG DAVID A | Director | Option Exercise | A | 16.05 | 10,000 | 160,500 | 10,000 | |
| Jul 07 2008 | PGNX | PROGENICS PHARMACE ... | DALTON MARK F | Director | Option Exercise | A | 16.05 | 10,000 | 160,500 | 10,000 | |
| Jul 07 2008 | PGNX | PROGENICS PHARMACE ... | GOFF STEPHEN P | Director | Option Exercise | A | 16.05 | 10,000 | 160,500 | 10,000 | |
| Jul 07 2008 | PGNX | PROGENICS PHARMACE ... | BAKER CHARLES A | Director | Option Exercise | A | 16.05 | 10,000 | 160,500 | 10,000 | |
| Jul 07 2008 | PGNX | PROGENICS PHARMACE ... | BRINER KURT W | Director | Option Exercise | A | 16.05 | 25,000 | 401,250 | 25,000 | |
| Jul 03 2008 | PGNX | PROGENICS PHARMACE ... | Olson William C | VP, Research & Deve ... | Option Exercise | A | 16.05 | 20,000 | 321,000 | 20,000 | |
| Jul 03 2008 | PGNX | PROGENICS PHARMACE ... | Olson William C | VP, Research & Deve ... | Option Exercise | A | 15.87 | 610 | 9,681 | 610 | |
| Jul 03 2008 | PGNX | PROGENICS PHARMACE ... | Olson William C | VP, Research & Deve ... | Option Exercise | M | 13.64 | 2,296 | 31,317 | 0 | |
| Jul 03 2008 | PGNX | PROGENICS PHARMACE ... | Olson William C | VP, Research & Deve ... | Grant | A | 0.00 | 6,667 | 0 | 36,622 | 30 K to 36.6 K (+22.26 %) |
| Jul 03 2008 | PGNX | PROGENICS PHARMACE ... | Olson William C | VP, Research & Deve ... | Payment of Exercise | F | 16.05 | 2,089 | 33,528 | 29,955 | 32 K to 30 K (-6.52 %) |